The non surgical periotherepy are based on the bacteriologic back ground of periodontal diseases.More than 46 different verulant species were composing the bacterial flora. Tetracycline, doxycyline, minocyline were used systemically and / or topically in association with conventional scaling and root planning, as well chlorhexidine and wide variety of antiseptics were used. Rapidly progressive type A and type B being a complex disease showing a specific entity and a complex bacterial flora, a curative non surgical remedy not yet well realized.The polyvinyl pyrrolidone (PVP) a highly effective wide broad spectrum bactericidal, fungicidal and virocidal antiseptic used in low concentration (3%) as an intrapocket irrigation solution accompanied with conventional ultrasound scaling and root planning. Eight patients having rapidly progressive periodontal (3 of type A , 5 of type B) were involved in this study, 12 therapeutic sessions were performed during 6 months. Once a week, in the first month, twice a month in the next 3 months, then once a month in the later 2 months. The result showed a significant improvement of the clinical parameters, gingival bleeding index (GBI), clinical pocket depth (CDD) and clinical tooth mobility (CTM) and with radiologic evidences of bone formation.The result suggests that PVP could be the promising effective, safe, clinically applicable, easy to use, and cheap remedy of complex periodontal diseases.

Acne vulgaris is a common skin disease.The therapeutic approach to this disease includes standard topical and systemic agents to newlyintroduced alternative medications.This study suggests a new indication for clofibrate (the lipid lowering agent) & that is to be usedtopically in the treatment of acne vulgaris. The proposed mechanism is by decreasing lipidbiosynthesis which takes place in the sebaceous gland.A total of 60 patients with visible papules and pustules of severe acne were enrolled in this study .Their age range between 13 – 31 years (24 males & 36 females).Healthy age matched controls (30 subjects) without any skin diseases were also participated is thisstudy.Clinical investigations involved disappearance of signs and symptoms of the disease while thebiochemical investigations involved measuring total cholesterol, HDL, LDL, & TG levels, SGOT,SGPT in the sera of all volunteers done before and 10 days after the topical application of clofibrate(500mg once daily).The effectiveness of the topical application of clofibrate was approved in the treatment of acnevulgaris as a new clinical application of this drug and a novel strategy for the treatment of the diseaseas there was significant improvement 75% of the patients & moderate improvement for the rest of thepatients .In comparison with controls, patients with acne had higher total serum cholesterol and LDL levelswith no significant difference in TG, HDL & enzyme levels. However, after the topical application of clofibrate, total serum cholesterol and LDL levels weredecreased while no significant changes observed in the TG, HDL, GOPT, GPT serum levels.The results revealed that circulating lipid were slightly higher in patients with acne than controlsubjects but declined after treatment. Healing was accompanied with improvement in the symptoms ofthe disease. This might suggest that the lipid profile is one of the contributing or aggravating factorsfor this disease.

A comparison was done between captopril, valsartan, carvedilol & the conventional therapy in patients with heart failure. The difference was reflected on the survival rate and hospital admissions. Eighty patients were enrolled in this study, all were diagnosed as having heart failure (Class I – IV).They were grouped into four groups each consisted of 20 patients. group I were given captopril 25mg twice daily,group II were given valsartan 80mg once daily,group III had carvedilol 12.5mg twice daily, and group IV were given the conventional therapy (digoxin, diuretics, nitrates …. etc.).Blood pressure and heart rate were checked at baseline (before treatment) & after one and two months after initiation therapy. Data were compared to those of 15 healthy & subjects included in the study as well.Results revealed that a significant (p<0.05) reduction in blood pressure was noticed for the four groups. The heart rate was increased significantly (p<0.05) in the captopril & valsartan groups after two months while decreased significantly following carvedilol & conventional treatment.As a whole, a high percentage of improvement in the functional class of NYHA was found in the valsartan (80%) & the carvedilol (70%) groups, as no health deterioration was noticed in any of these two groups & no one died. While the improvement percentage was to a lesser extent among patients on captopril the conventional therapy (10% and 20% respectively) with reported deaths.The number of hospitalization during the follow up period was reduced significantly (p<0.001) in the valsartan and carvedilol groups and to a lesser extent in the captopril group while there was no significant reduction in hospital admissions of patients on the conventional therapy.According to this, carvedilol or valsartan improved cardiac function, quality of life, reduced mortality and morbidity in patients with heart failure leading to a better short & long term prognosis.